<div id="readability-page-1"><div> Health-care companies rose as defensive-minded traders rotated into the sector, which is viewed as relatively evergreen. Precious metals had been the preferred safe haven during recent domestic and geopolitical instability. Traders abruptly fled those investments following the unveiling of former Federal Reserve governor Kevin Warsh as President Trump's Fed nominee. Warsh was a much more conventional and possibly less dovish choice than market participants had anticipated. Drug giant Eli Lilly unveiled plans to open a $3.5 billion plant to produce weight-loss drugs in Pennsylvania's Lehigh Valley, giving the region an economic shot in the arm. British drug maker AstraZeneca said it entered into a collaboration agreement with China's CSPC Pharmaceuticals to gain rights to a portfolio of early-stage experimental obesity and diabetes drugs, in a deal potentially valued at billions of dollars. Pfizer and Merck rose ahead of earnings next week. Health insurers remained under pressure due to concerns about the Trump administration's proposed rates for Medicare reimbursement. <pre></pre> Write to Rob Curran at rob.curran@dowjones.com (END) Dow Jones Newswires January 30, 2026 17:46 ET (22:46 GMT)Copyright (c) 2026 Dow Jones &amp; Company, Inc.</div></div>

生物科技 ETF - VanEck Vectors

新諾威

IBBQ

醫療股因市場不穩定而受到交易者的關注而上漲。禮來宣佈將在賓夕法尼亞州投資 35 億美元建設減肥藥工廠，而阿斯利康則與新諾威合作獲得肥胖和糖尿病藥物的權益。輝瑞和默克在即將公佈的財報前實現了上漲，但健康保險公司面臨特朗普政府提出的醫療保險報銷率的壓力

Health Care Up After Defensive Rotation — Health Care Roundup

- 醫療保健公司因交易者轉向其為防禦性投資而上漲。  
- Eli Lilly 在賓夕法尼亞州計劃投資 35 億美元建設減肥藥工廠。  
- 阿斯利康與中國 CSPC 製藥達成合作，尋求肥胖和糖尿病藥物的權利。

MorningStar

Invesco Nasdaq Biotechnology ETF

醫療業 ETF - SPDR

2 倍做多納斯達克生物技術 ETF - ProShares

醫藥突破 ETF - ALPS

納斯達克生物科技指數 ETF - iShares Nasdaq

輝瑞

美國制藥 ETF - iShares

基因改革 ETF - ARK

2 倍做多 LLY ETF - Direxion

2 倍做多 LLY ETF - Defiance

動態生物技術與基因組 ETF - Invesco

標普全球醫療股指數 ETF - iShares

禮來

醫療業 ETF - Vanguard

默克

在防禦性輪換之後，醫療保健板塊上漲——醫療保健綜述